Ascendia

  MARKET NEWS

Terns Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of Oral GLP-1 Receptor Agonist for Obesity Treatment
ARTIDIS Launches Groundbreaking ANGEL Study With Over 2,700 Participants: Transforming Breast Cancer Diagnosis & Personalized Therapy Optimization at the Patient's Bedside
Vaxart Doses First Subject in Phase 1 Trial of its Norovirus Vaccine Candidate in Lactating Mothers
Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting With FDA for Oral APX3330 in Diabetic Retinopathy
Tract Bio Announces Publication Highlighting Stem Cell Variants Driving Lung Inflammation in Modulator-Treated Cystic Fibrosis Patients
Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD

  FEATURED EDITORIAL

  COMPANY PROFILE

For over 30 years, DDL has provided extraordinary service and specialized testing expertise to the medical device and pharmaceutical industries. Our reliable quality, responsive attention, and on-schedule completion for packaging, medical device, and combination products testing secures confidence in performance and safety while achieving regulatory compliance. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Cambrex Announces Sale of Drug Product Business Unit

Cambrex Announces Sale of Drug Product Business Unit

Cambrex recently completed the sale of its Drug Product Business Unit to Wilmington, DE- based Noramco. Cambrex’s Drug Product business provides….

Sitryx Announces Partner Eli Lilly & Company Exercises Option to SIT-011 for Chronic Autoimmune & Inflammatory Diseases

Sitryx Announces Partner Eli Lilly & Company Exercises Option to SIT-011 for Chronic Autoimmune & Inflammatory Diseases

Sitryx Therapeutics recently announced Eli Lilly & Company has exercised its option to progress SIT-011. Lilly will now lead further development and commercialization of the Phase 1 ready….

Lexaria Bioscience Evaluating Proprietary Drug Delivery Platform for Improved Efficacy of GLP-1 Drugs

Lexaria Bioscience Evaluating Proprietary Drug Delivery Platform for Improved Efficacy of GLP-1 Drugs

Lexaria Bioscience Corp. began diabetes-related formal studies last year with its DehydraTECH platform, which showed reduced blood-sugar levels and lowered body weight…..

In the Global Market for Self-Injected Therapies, Vetter Sees Both Opportunities & Challenges

In the Global Market for Self-Injected Therapies, Vetter Sees Both Opportunities & Challenges

In just the last few years, the shift toward at-home, self-administered care has become one of the defining trends in the global market for injectable therapies…..

Karyopharm Announces Clinical Trial Collaboration With Bristol Myers Squibb

Karyopharm Announces Clinical Trial Collaboration With Bristol Myers Squibb

Karyopharm Therapeutics Inc. recently announced it has entered into a clinical trial collaboration and supply agreement with Bristol-Myers Squibb to evaluate the company’s proprietary investigational….

  WHITEPAPERS & WEBINARS

WEBINAR - Nanoparticle Suspensions: History, Applications & CMC Aspects

WEBINAR - Nanoparticle Suspensions: History, Applications & CMC Aspects

This webinar describes the history, CMC aspects, and potential applications of nanoparticle suspensions (NSs). This drug delivery technology should be considered for crystalline, sparingly water-soluble APIs. The presentation highlights….

WEBINAR - Impact of Process Re-design on Sustainability in Pharmaceutical Small Molecule Manufacturing

WEBINAR - Impact of Process Re-design on Sustainability in Pharmaceutical Small Molecule Manufacturing

Join us for an upcoming webinar that delves into a crucial issue in the pharmaceutical industry. Recent research has revealed a surprising fact: the pharmaceutical sector has a larger carbon footprint than even the automotive industry, especially when we consider the entire supply chain’s impact on

WEBINAR - Beyond the Lab: Unleashing the Potential of In Silico Modeling in Drug Product Formulation

WEBINAR - Beyond the Lab: Unleashing the Potential of In Silico Modeling in Drug Product Formulation

In this webinar you will learn how digital chemistry tools facilitate rapid screening of formulation parameters, aiding in the identification of optimal drug delivery systems, excipient selection, and dosage forms….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination

WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination

Owing its convenience, oral administration is patients’ preferred route of delivery for therapeutic molecules. However, most New Chemical Entities (NCE) exhibit physico-chemical properties limiting their absorption in the gastro-intestinal (GI) tract. Indeed, according to Pharmacircle data from March 2022, almost …

WHITEPAPER: Innovating Pharma Barrier Packaging for a Sustainable Future

WHITEPAPER: Innovating Pharma Barrier Packaging for a Sustainable Future

Honeywell Aclar® thermoformable film enables pharmaceutical and medical device companies to achieve their sustainability commitments.

Aclar® film not only delivers a high moisture barrier to protect medicines, but it also reduces pack size, reduces waste, and reduces carbon emissions, compared

…

WHITEPAPER - Copolymer Microstructures: Connecting Monomer Sequence Distribution With Biomedical End-Application Performance

WHITEPAPER - Copolymer Microstructures: Connecting Monomer Sequence Distribution With Biomedical End-Application Performance

By: Dr. Bahar Yeniad and Dr. Pieter van Delft

Experts in copolymer microstructures have an important role to play in selecting biomaterials that can deliver desired performance of (bio)medical products. But how does microstructure link to the rate of API …

WHITEPAPER - Monitoring Low Dose API Blend Uniformity With Parteck® M Mannitol Using Near-Infrared (NIR) Spectroscopy

WHITEPAPER - Monitoring Low Dose API Blend Uniformity With Parteck® M Mannitol Using Near-Infrared (NIR) Spectroscopy

Direct compression is often used for tablet manufacturing because it is the shortest, most effective, and least complex method. The physical properties of active pharmaceutical ingredients (APIs) can, however, create a challenge for flowability and compressibility, and, as a result, …

WHITEPAPER - The Viscosity Reduction Platform: Viscosity-Reducing Excipients for Protein Formulation

WHITEPAPER - The Viscosity Reduction Platform: Viscosity-Reducing Excipients for Protein Formulation

Protein viscosity is one of the major obstacles in preparing highly concentrated protein formulations suitable for subcutaneous (subQ) injection. SubQ application of highly concentrated protein formulations enables a higher patient convenience and might thus lead to reduction in health costs. …

WHITEPAPER - Streamline Early-Stage Development to Reach the Clinic Faster

WHITEPAPER - Streamline Early-Stage Development to Reach the Clinic Faster

Early-stage development is critical to shortening your product’s timelines while establishing a solid foundation for clinical trials. In this insightful article from Dr. Srinivasan Shanmugam, Adare’s Executive Director of Pharmaceutical Sciences, learn what’s needed to make your product’s early-stage development …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

November 15 – Parenteral Contract Manufacturing
November 22 – Particle Design Technology